PFS = progression-free survival
Community-driven development of a modified progression-free survival ratio for precision oncology
... Figure 1 Physician- perceived clinical benefit of molecularly guided therapy. (A) PFS1 and PFS2 times of 194 patients enrolled in the MOSCATO 01 trial. (B) Examples of response assessments by physicians based on PFS1 and ...
7
Negative effect of hepatitis in overall and progression-free survival among patients with diffuse large B-cell lymphoma
... ALT: Alanine aminotransferase; ALT: Alanine Transaminae; AST: Aspartate aminotransferase; CR: Complete response; DLBCL: Diffuse Large B Cell Lymphoma; ECOG: Eastern Cooperative Oncology Group; ESHAP: Etopside, ...
7
Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors
... low PFS figures (median 2–3 months) on patients with elevated CRP levels are highly suggestive of low or no benefit of anti-PD-(L)1 ...therapy. Survival outcomes of our cohorts were significant in the whole ...
7
Diffusion MR Characteristics Following Concurrent Radiochemotherapy Predicts Progression-Free and Overall Survival in Newly Diagnosed Glioblastoma.
... sion-free survival (PFS) and overall survival (OS) in GBM pa- tients treated with bevacizumab at recurrence ...longer PFS and OS, whereas patients with low ADC measurements have a ...
8
Piwil 2 Expression Is Correlated with Disease-Specific and Progression-Free Survival of Chemotherapy-Treated Bladder Cancer Patients
... tumor progression (P = ...mean survival was de- tected in the group with negative nuclear staining ...tumor progression was observed for the patients with a negative nuclear ...
10
Overexpression of G6PD is associated with high risks of recurrent metastasis and poor progression free survival in primary breast carcinoma
... Furthermore, Cox multivariate analyses indicated that the G6PD protein was an independent prognostic fac- tor for mean PFS, consistent with previous study. Pa- tients with low expression of G6PD were more likely ...
7
Challenges and methodologies in using progression free survival as a surrogate for overall survival In oncology
... surrogate. Progression-free survival (PFS) is the surrogate most often used in oncology, but does not always satisfy the correlation conditions for ...from PFS to ...between PFS ...
24
hGBP 1 Expression Predicts Shorter Progression Free Survival in Ovarian Cancers, While Contributing to Paclitaxel Resistance
... Shorter PFS To determine if the expression of hGBP-1 in newly isolated ovarian tumors altered dis- ease prognosis, PFS of patients with ovarian tumors was determined for tumors with low or high initial ...
14
Original Article Impact of LGR5 in colorectal cancer on overall and progression-free survival: a systematic review and meta-analysis
... In summary, the present meta-analysis indi- cates that LGR5 expression is associated with a poor OS, PFS, and a higher TNM stage. And no correlation was found between LGR5 expres- sion and tumor differentiation. ...
7
Smoking is predictive of poorer distant metastasis-free and progression free-survival in soft tissue sarcoma patients treated with pre-operative radiotherapy or chemoradiotherapy
... Background: Soft tissue sarcomas (STS) are often treated with pre-operative radiation (RT), with or without chemo- therapy, followed by wide local excision. Prognosis for these patients involves an interplay of tumor and ...
7
Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2− metastatic breast cancer?
... in PFS in 1L therapy. Among the 19 1L studies that reported significant PFS improvement, 9 were of tyrosine kinase inhibitors (TKI) plus chemotherapy (CHEMO) and 3 were of CDK 4/6 inhibitor plus ET ...
11
Interpreting overall survival results when progression-free survival benefits exist in today's oncology landscape: a metastatic renal cell carcinoma case study
... a PFS difference exists, when making the assumption of no treatment effect on ...for PFS was ...until progression (during which PFS is measured) is small in relation to the median ...
7
Response and Progression Free Survival in Oropharynx Squamous Cell Carcinoma Assessed by Pretreatment Perfusion CT: Comparison with Tumor Volume Measurements
... the PFS according to the initial tumor volume and the BF value, and 2) a model that will identify patients who have a high probability of re- sponding to induction ...of survival according to the demon- ...
7
Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression free and overall survival in both old and recent myeloma trials
... appropriate. Survival curves were constructed using the method of Kaplan and Meier, and the log-rank test was used to assess the differences between the groups, in the old myeloma trials and recent myeloma trials ...
12
Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma
... durable PFS in selected patients. We have shown that long PFS is associated with progression limited to established tumors, while local therapy for new metastases is associated with early relapse and ...
9
Long-term progression-free survival in an advanced lung adenocarcinoma patient harboring EZR-ROS1 rearrangement: a case report
... Crizotinib is approved by the US Food and Drug Admin- istration (FDA) for the first-line treatment of NSCLC pa- tients with ROS1 rearrangements with a median PFS of at least 19.2 months [6, 11]. Pemetrexed-based ...
5
RRM1 single nucleotide polymorphism -37C→A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy
... Between March 2006 and February 2007, 62 eligible patients were enrolled. The patients’ ages ranged from 35 to 70 years (median, 61); 21 were women. Among the 62 patients, 59 were naive to any previous antican- cer ...
8
Impact of red blood cell transfusion dose density on progression-free survival in lower-risk myelodysplastic syndromes patients
... Unadjusted PFS stratified by transfusion status and dose density (untransfused n=751, low dose density n=258, high dose density=258) at the third visit is presented in figure ...overall PFS of the three ...
30
P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy
... on PFS in mtp53 tumors is not dependent on ...to PFS also limits the firmness with which conclusions can be made, even in the presence of a multivariate ...
10
Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma
... Our study revealed that high pretreatment serum sPD-L1 levels and low treatment response (less than PR) were independent prognostic factors for lower PFS. Additionally, serum sPD-L1 level was a strong predictor of ...
9